Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX-463 for idiopathic pulmonary fibrosis
2025-521278-32-00Phase 2Authorised
- Sponsor
- Mediar Therapeutics
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing MTX-463 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 24 in forced vital capacity. Planned start Dec 2025; status: authorised.
02
Drugs
MTX-463
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2025-521278-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521278-32-00.